

Pioglitazone has limited effect in lipoatrophic diabetes

September 20 2017



(HealthDay)—Pioglitazone may not be effective for lowering blood

glucose levels, although it is associated with slight improvement in liver function, in lipoatrophic diabetes induced by juvenile dermatomyositis, according to a case report published online Sept. 12 in the *Journal of Diabetes Investigation*.

Yusuke Baba, M.D., from the Chiba University Graduate School of Medicine in Japan, and colleagues present a case of lipoatrophic diabetes induced by juvenile dermatomyositis. A 19-year-old male was admitted for treatment of poorly controlled diabetes; he had been diagnosed with juvenile dermatomyositis at age 3, and was diagnosed with diabetes at age 9.

The authors note that pioglitazone improved [liver function](#) slightly, although it was not effective for lowering [blood glucose levels](#), with no change seen in blood glucose and hemoglobin A1c levels. Metreleptin was only administered for a short period, and consequently its effectiveness could not be ascertained. Burned-out nonalcoholic steatohepatitis was revealed on [liver biopsy](#).

"Our results indicate that the successful treatment of lipoatrophic diabetes induced by juvenile dermatomyositis requires an early diagnosis and therapeutic intervention," the authors write.

More information: [Abstract](#)
[Full Text](#)

Copyright © 2017 [HealthDay](#). All rights reserved.

Citation: Pioglitazone has limited effect in lipoatrophic diabetes (2017, September 20) retrieved 18 April 2024 from <https://medicalxpress.com/news/2017-09-pioglitazone-limited-effect-lipoatrophic-diabetes.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.